TC Biopharm (Holdings) Plc (TCBP)
NASDAQ: TCBP · IEX Real-Time Price · USD
0.891
+0.056 (6.74%)
At close: Jul 2, 2024, 3:58 PM
0.913
+0.022 (2.43%)
After-hours: Jul 2, 2024, 7:54 PM EDT
Company Description
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform.
Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.
The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
TC Biopharm (Holdings) Plc
| Country | United Kingdom |
| Founded | 2013 |
| IPO Date | Feb 11, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Bryan L. Kobel |
Contact Details
Address: Maxim 1, 2 Parklands Way Holytown, X0 ML1 4WR United Kingdom | |
| Phone | 01414337557 |
| Website | tcbiopharm.com |
Stock Details
| Ticker Symbol | TCBP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| IPO Price | $4.25 |
| CIK Code | 0001872812 |
| CUSIP Number | 87807D103 |
| ISIN Number | US87807D4007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bryan L. Kobel | Chief Executive Officer and Director |
| Martin E. Thorp | Chief Financial Officer and Director |
| Christopher Camarra | Executive Vice President of Communications |
| Dr. Lauren Bor Ph.D. | Head of Commercial Development Division |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Jul 1, 2024 | 6-K | Report of foreign issuer |
| Jul 1, 2024 | 6-K | Report of foreign issuer |
| Jun 28, 2024 | 8-K | Current Report |
| Jun 26, 2024 | 424B3 | Prospectus |
| Jun 24, 2024 | EFFECT | Notice of Effectiveness |
| Jun 20, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Jun 7, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 6, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 29, 2024 | 8-K | Current Report |